

Ontario Pharmacists' Association

Opioid and Pain Management in Pharmacy Program (OPMPP) – Advisory Group

Terms of Reference

MANDATE

The Ontario Pharmacists Association (OPA) is committed to advancing excellence in practice and patient care with a goal to foster inspiration, innovation, and opportunity for every pharmacy professional in Ontario. The opioid crisis continues to have a serious impact on Canadians and their communities with the continued rise in opioid-related deaths and its significant economic impact on the health care system. In considering the impact of opioid prescriptions and the potential role pharmacists can play in opioid stewardship, OPA is leading research to help inform policies that can contribute to curbing the crisis. The Opioid and Pain Management in Pharmacy Program (OPMPP) Advisory Group will provide strategic direction, facilitate ongoing discussion, and inform OPA on the creation and implementation of a pain management program in Ontario community pharmacies, with the wider goal of creating a standardized and sustainable program.

OBJECTIVES

To support the development and implementation of a pain management program in community pharmacies that can:

- Demonstrate the impact pharmacy professionals could have on improving pain management for patients, supporting appropriate prescribing and dispensing of opioids, and supporting the safe and appropriate use of opioids to minimize potential opioid misuse, abuse and harm.
- Inform and support the development of a new and sustainable comprehensive pain management program that will help to address the opioid crisis by enabling greater patient access to these pharmacy services.

ROLES & RESPONSIBILITIES

- To advise on the development, provision and revision of a pain management program in Ontario community pharmacies
 - Program development proposal
 - Program implementation tools (e.g., infographics, screening tools, documentation templates, professional development courses)
 - The program's plan for analysis
- To make recommendations that will drive uptake and sustainable operationalization of the program

- To support dissemination (e.g., identifying opportunities to promote the program/results where applicable and appropriate, promote program/evaluation results within organization and professional networks)

MEMBERSHIP

Members will include representation from relevant stakeholders including:

- Practicing community pharmacists/owners
- Individuals with lived experience
- Prescribers/primary care providers
- Knowledge experts (e.g., from the Centre for Addiction and Mental Health (CAMH), the Institute for Safe Medical Practices (ISMP) Canada.

The advisory group will be chaired by a delegate representing OPA staff and OPA staff delegates will also support all meetings.

LENGTH OF TERM

The MHA advisory group will carry out its work over an estimated timeframe of 12 months – beginning in 2023 and will be contingent on continued funding.

MEETINGS/COMMITMENT

Four virtual meetings (up to 4 hours each) are scheduled to occur February, April, July and October 2023, time and specific dates to be determined. Meeting times will be communicated in advance based on the Advisory Group's availability. If there are unexpected delays in the development process, OPA will inform all Advisory Group members at least one month in advance. In addition to attending meetings, the group will be expected to work independently to review any pre-reading materials (e.g., drafts of deliverables). All Advisory Group meeting materials are assumed to be confidential and are not for wider distribution, unless otherwise stated.

FUNDING

This program is funded by the Mental Health and Addictions Program under Ontario Health. OPA will continue to apply each year for continued funding.

RECOGNITION

The contributions of the OPMPP advisory group will be named through an acknowledgement in any publications or disseminations of the program or evaluation results.

HONORARIUM

Each member is eligible to claim a per diem of \$162.50 per meeting that they attend.

CONFLICTS OF INTEREST

Members must make a declaration of any potential financial, professional, intellectual, personal, organizational or other relationships as outlined in the consent and conflicts of interest (COI) form.